TFS
WST icon

Thoroughbred Financial Services’s West Pharmaceutical WST Stock Holding History

Thoroughbred Financial Services’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,733
Closed -$611K – 714
2025
Q1 		$611K Sell
2,733
-14
-0.5% -$3.86K 0.04% 377
2024
Q4 		$899K Sell
2,747
-149
-5% -$46.9K 0.05% 295
2024
Q3 		$869K Buy
2,896
+220
+8% +$67.4K 0.06% 303
2024
Q2 		$881K Buy
2,676
+2,036
+318% +$720K 0.06% 287
2024
Q1 		$253K Sell
640
-2,103
-77% -$778K 0.02% 405
2023
Q4 		$965K Sell
2,743
-39
-1% -$13.8K 0.08% 245
2023
Q3 		$1.04M Buy
2,782
+2,142
+335% +$828K 0.1% 203
2023
Q2 		$244K Hold
640
– – 0.03% 360
2023
Q1 		$221K Buy
+640
New +$187K 0.03% 377
2022
Q3 		– Sell
-860
Closed -$260K – 388
2022
Q2 		$260K Sell
860
-55
-6% -$17.9K 0.05% 311
2022
Q1 		$375K Buy
+915
New +$358K 0.06% 259

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Thoroughbred Financial Services's WST Position: Q2 2025 in Review

Thoroughbred Financial Services sold out of West Pharmaceutical (WST) in Q2 2025, closing a stake of 2,733 shares — an estimated $611K sold.

Thoroughbred Financial Services first reported a position in WST in Q1 2022 and held it in 11 quarters. The position peaked at $1.04M in Q3 2023. 730 funds tracked by Wall St. Rank hold WST as of Q2 2025.

  • Thoroughbred Financial Services reported no remaining West Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Thoroughbred Financial Services sold 2,733 West Pharmaceutical shares in Q2 2025, an estimated $611K.
  • Thoroughbred Financial Services first reported a position in West Pharmaceutical in Q1 2022 and held it in 11 quarters.
  • Thoroughbred Financial Services's West Pharmaceutical position peaked at $1.04M in Q3 2023.
  • 730 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2025.

Based on Thoroughbred Financial Services's 13F filing for Q2 2025, filed 8 Aug 2025.